KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Accumulated Expenses (2018 - 2023)

Historic Other Accumulated Expenses for Esperion Therapeutics (ESPR) over the last 6 years, with Q4 2023 value amounting to $25.0 million.

  • Esperion Therapeutics' Other Accumulated Expenses rose 8932.14% to $25.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $25.0 million, marking a year-over-year increase of 8932.14%. This contributed to the annual value of $25.0 million for FY2023, which is 8932.14% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Other Accumulated Expenses of $25.0 million as of Q4 2023, which was up 8932.14% from $13.2 million recorded in Q4 2022.
  • Over the past 5 years, Esperion Therapeutics' Other Accumulated Expenses peaked at $30.4 million during Q4 2021, and registered a low of $3.2 million during Q1 2020.
  • Its 5-year average for Other Accumulated Expenses is $13.0 million, with a median of $10.9 million in 2019.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 24904.44% in 2019, then crashed by 5658.01% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Other Accumulated Expenses (Quarter) stood at $11.9 million in 2019, then surged by 108.83% to $24.8 million in 2020, then grew by 22.67% to $30.4 million in 2021, then tumbled by 56.58% to $13.2 million in 2022, then skyrocketed by 89.32% to $25.0 million in 2023.
  • Its last three reported values are $25.0 million in Q4 2023, $13.2 million for Q4 2022, and $30.4 million during Q4 2021.